What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By hitting both incretin receptors simultaneously, it produces superior weight loss compared to GLP-1 agonists alone. The SURMOUNT-1 trial showed an average 22.5% body weight reduction — the highest ever recorded in a pharmaceutical weight loss trial.
Mechanism of Action
Tirzepatide activates both GIP and GLP-1 receptors. GIP receptor activation enhances the GLP-1 effects on appetite suppression, improves adipose tissue metabolism (fat burning), and reduces the nausea side effects common with pure GLP-1 agonists. The dual mechanism produces synergistic effects on weight loss, insulin sensitivity, and metabolic health.
Tirzepatide Dosing Protocol
Start at 2.5 mg/week subcutaneous for 4 weeks → increase by 2.5 mg every 4 weeks → target dose 5–15 mg/week. Maximum approved dose: 15 mg/week. Inject once weekly.
Want a personalized protocol? Tell PepBot your goals, health status, and experience level for a custom Tirzepatide protocol.
Tirzepatide Benefits
Side Effect Profile
Nausea, diarrhea, vomiting (less than Semaglutide due to GIP component). Constipation. Rare: pancreatitis. Titrate slowly.
Tirzepatide Stacking Guide
Tirzepatide works synergistically with these compounds. Click any to learn more, or ask PepBot to build you a complete stack.
Research & Citations
Frequently Asked Questions about Tirzepatide
Is Tirzepatide better than Semaglutide?
Still have questions about Tirzepatide?
PepBot has encyclopedic knowledge of Tirzepatide — dosing, stacking, interactions, latest research, and personalized protocols. Ask anything.